SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Mi Na Kim, Chun Kyon Lee, Sang Hoon Ahn, Sangheun Lee, Seung Up Kim, Do Young Kim, Hyon Suk Kim, Kwang-Hyub Han, Chae Yoon Chon, Jun Yong Park, Maintaining remission in lamivudine-resistant patients with a virological response to adefovir add-on lamivudine after stopping lamivudine therapy, Liver International, 2014, 34, 10
  2. 2
    Benny S.P. Fok, Stephen Gardner, Steve Piscitelli, Shuguang Chen, Tanya T.W. Chu, Jones C.M. Chan, Brian Tomlinson, Pharmacokinetic Properties of Single-Dose Lamivudine/Adefovir Dipivoxil Fixed-Dose Combination in Healthy Chinese Male Volunteers, Clinical Therapeutics, 2013, 35, 1, 68

    CrossRef

  3. You have free access to this content3
    Geoffrey Dusheiko, Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues, Liver International, 2013, 33,
  4. 4
    Hui-Hui Tan, Paul Martin, Management of End-Stage Liver Disease in Chronic Hepatitis B, Clinics in Liver Disease, 2010, 14, 3, 477

    CrossRef

  5. 5
    Yun–Fan Liaw, Edward Gane, Nancy Leung, Stefan Zeuzem, Yuming Wang, Ching Lung Lai, E. Jenny Heathcote, Michael Manns, Natalie Bzowej, Junqi Niu, Steven–Huy Han, Seong Gyu Hwang, Yilmaz Cakaloglu, Myron J. Tong, George Papatheodoridis, Yagang Chen, Nathaniel A. Brown, Efsevia Albanis, Karin Galil, Nikolai V. Naoumov, 2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B, Gastroenterology, 2009, 136, 2, 486

    CrossRef

  6. 6
    R. Idilman, S. Kaymakoglu, F. Oguz Onder, E. Ahishali, M. Bektas, K. Cinar, B. Pınarbasi, S. Karayalcin, S. Badur, Y. Cakaloglu, A. Mithat Bozdayi, H. Bozkaya, A. Ökten, C. Yurdaydin, A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients, Journal of Viral Hepatitis, 2009, 16, 4
  7. 7
    Choong Keun Cha, Hyeok Choon Kwon, Jae Youn Cheong, Sung Won Cho, Sun Pyo Hong, Soo-Ok Kim, Wang Don Yoo, Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B, Journal of Medical Virology, 2009, 81, 3
  8. 8
    Cesare Sarrecchia, Antonio Volpi, Pasquale Sordillo, Massimo Andreoni, Multidrug resistance after lamivudine therapy for chronic hepatitis B, International Journal of Infectious Diseases, 2009, 13, 3, e133

    CrossRef

  9. 9
    Hie-Won Hann, Vicki L. Gregory, Jonathan S. Dixon, Keith F. Barker, A review of the one-year incidence of resistance to lamivudine in the treatment of chronic hepatitis B, Hepatology International, 2008, 2, 4, 440

    CrossRef

  10. 10
    Yun-Fan Liaw, Nancy Leung, Jia-Horng Kao, Teerha Piratvisuth, Edward Gane, Kwang-Hyub Han, Richard Guan, George K. K. Lau, Stephen Locarnini, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update, Hepatology International, 2008, 2, 3, 263

    CrossRef

  11. 11
    Jong-Kee Kim, Hyeon-Ji Lee, Young-Jo Lee, Jong-Yoon Chun, In-Kyoung Lee, Young-Suk Lim, Dong Jin Suh, Sun-Young Ko, Myeong Hee Kim, Heung-Bum Oh, Direct detection of lamivudine-resistant hepatitis B virus mutants by a multiplex PCR using dual-priming oligonucleotide primers, Journal of Virological Methods, 2008, 149, 1, 76

    CrossRef

  12. 12
    Rong-Nan Chien, Yun-Fan Liaw, Nucleos(t)ide analogues for hepatitis B virus: Strategies for long-term success, Best Practice & Research Clinical Gastroenterology, 2008, 22, 6, 1081

    CrossRef

  13. 13
    Nancy Leung, Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues, Hepatology International, 2008, 2, 2, 163

    CrossRef

  14. 14
    Ilan S. Weisberg, Robert S. Brown, Samuel H. Sigal, Hepatitis B and End-Stage Liver Disease, Clinics in Liver Disease, 2007, 11, 4, 893

    CrossRef

  15. 15
    Yun-Fan Liaw, Towards a rational treatment strategy for chronic hepatitis B, Hepatology International, 2007, 1, 2, 285

    CrossRef